Upcoming Investor Conferences for Erasca, Inc.
Erasca, Inc. (NASDAQ: ERAS) is a pioneering clinical-stage precision oncology company dedicated to advancing therapies for patients battling RAS/MAPK pathway-driven cancers. The company recently highlighted its participation in several notable investor conferences, providing a platform for their management team to connect with investors and share their vision for cancer treatment innovation.
Guggenheim Securities Healthcare Innovation Conference
This event is scheduled to take place from November 11 to November 13, featuring a fireside chat format. Erasca will present on November 12 at 2:00 pm Eastern Time at the InterContinental Hotel in Boston.
Jefferies London Healthcare Conference
Following the Guggenheim event, Erasca will participate in the Jefferies London Healthcare Conference from November 19 to November 21. The company is set to deliver a presentation on November 20 at 12:30 pm Greenwich Mean Time, held at The Waldorf Hilton in London, UK.
7th Annual Evercore HealthCONx Conference
The final event on the list is the 7th Annual Evercore HealthCONx Conference, occurring from December 3 to December 5. Erasca will take part in another fireside chat on December 4 at 11:15 am Eastern Time, located at the Loews Coral Gables Hotel in Florida.
Strategies for Engagement
Erasca remains committed to transparency and investor engagement, offering a live audio webcast of each conference. This facilitates access for those unable to attend in person. Archived replays will be accessible for 90 days, enabling interested parties to stay updated on Erasca's developments and insights into their innovative approaches.
About Erasca
At Erasca, the team is driven by a clear mission: to erase cancer. This clinical-stage precision oncology company focuses intently on discovering and developing novel therapies aimed at halting cancer's progression, particularly within patients whose cancers are driven by the RAS/MAPK pathway. Established by luminaries in precision oncology, Erasca is dedicated to creating new therapies and treatment combinations that effectively disrupt this crucial pathway.
The company has developed an extensive pipeline focused on RAS/MAPK, signaling a commitment to pioneering solutions that cater to pressing medical needs. Bolstered by a distinguished scientific advisory board composed of global experts, Erasca is well-positioned to pursue its ambitious aim of revolutionizing cancer treatment.
Contact Information
For inquiries, please reach out to: Joyce Allaire
LifeSci Advisors, LLC
Email: jallaire@lifesciadvisors.com
Frequently Asked Questions
What is Erasca, Inc.'s main focus?
Erasca, Inc. is focused on discovering and developing therapies for patients with RAS/MAPK pathway-driven cancers.
When will Erasca present at the Guggenheim Securities Conference?
Erasca will present at the Guggenheim Securities Healthcare Innovation Conference on November 12 at 2:00 pm Eastern Time.
Where is the Jefferies London Healthcare Conference being held?
This conference will take place at The Waldorf Hilton, London, UK, from November 19 to 21.
How does Erasca ensure investor engagement?
Erasca provides a live audio webcast of their presentations at investor conferences, along with archived replays for additional accessibility.
Who should I contact for more information about Erasca?
For more details, you can contact Joyce Allaire at LifeSci Advisors via her email: jallaire@lifesciadvisors.com.
